Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Mar;84(5):651–658. doi: 10.1054/bjoc.2000.1658

Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer

A Paradiso 1, G Simone 2, M De Lena 3, B Leone 4, C Vallejo 4, J Lacava 4, S Dellapasqua 5, M G Daidone 5, A Costa 5
PMCID: PMC2363782  PMID: 11237386

Abstract

The clinical relevance of bax and bcl-2 protein expression has been investigated in 84 patients with recurrent or metastatic colorectal cancer submitted to a chemotherapy regimen including methotrexate and fluorouracil/leucovorin. Cytoplasmic immunostaining of bax and bcl-2 was present in 65.5% and 38%, respectively, of the tumours. No association was found between bax and bcl-2 or between p53 and bax or bcl-2 protein expression. Moreover, the biomarkers were unrelated to patient and tumour characteristics known to affect the clinical outcome of colorectal cancer patients. In general, the apoptosis-related markers did not appear indicative of short- and long-term clinical response nor of prognosis. Bcl-2-negative lesions were more frequent among patients who reached an objective clinical response, which is in agreement with previously reported data regarding other tumour types. When the interrelationship between p53 and bax expression was examined, a better response rate (40%) was found for patients whose tumours did not express p53 and bax, and a better prognosis (2-year probability of overall survival 75%) for patients with p53-positive and bax-negative tumours. In the present series of patients with advanced colorectal cancer submitted to systemic chemotherapy we did not find a clear association between expression of apoptosis-related markers and clinical outcome, even in the subset of patients in which the apoptotic index as determined by the TUNEL approach was investigated. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: bax expression, bcl-2 expression, advanced colorectal cancer, response to treatment, p53 expression, apoptotic index

Full Text

The Full Text of this article is available as a PDF (92.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdel-Rahman W. M., Georgiades I. B., Curtis L. J., Arends M. J., Wyllie A. H. Role of BAX mutations in mismatch repair-deficient colorectal carcinogenesis. Oncogene. 1999 Mar 25;18(12):2139–2142. doi: 10.1038/sj.onc.1202589. [DOI] [PubMed] [Google Scholar]
  2. Apolinario R. M., van der Valk P., de Jong J. S., Deville W., van Ark-Otte J., Dingemans A. M., van Mourik J. C., Postmus P. E., Pinedo H. M., Giaccone G. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol. 1997 Jun;15(6):2456–2466. doi: 10.1200/JCO.1997.15.6.2456. [DOI] [PubMed] [Google Scholar]
  3. Baretton G. B., Diebold J., Christoforis G., Vogt M., Müller C., Dopfer K., Schneiderbanger K., Schmidt M., Löhrs U. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer. 1996 Jan 15;77(2):255–264. doi: 10.1002/(SICI)1097-0142(19960115)77:2<255::AID-CNCR6>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
  4. Bargou R. C., Daniel P. T., Mapara M. Y., Bommert K., Wagener C., Kallinich B., Royer H. D., Dörken B. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer. 1995 Mar 16;60(6):854–859. doi: 10.1002/ijc.2910600622. [DOI] [PubMed] [Google Scholar]
  5. Bargou R. C., Wagener C., Bommert K., Mapara M. Y., Daniel P. T., Arnold W., Dietel M., Guski H., Feller A., Royer H. D. Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest. 1996 Jun 1;97(11):2651–2659. doi: 10.1172/JCI118715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Berney C. R., Downing S. R., Yang J. L., Russell P. J., Crowe P. J. Evidence for post-transcriptional down-regulation of the apoptosis-related gene bcl-2 in human colorectal cancer. J Pathol. 2000 May;191(1):15–20. doi: 10.1002/(SICI)1096-9896(200005)191:1<15::AID-PATH566>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  7. Bubb V. J., Curtis L. J., Cunningham C., Dunlop M. G., Carothers A. D., Morris R. G., White S., Bird C. C., Wyllie A. H. Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer. Oncogene. 1996 Jun 20;12(12):2641–2649. [PubMed] [Google Scholar]
  8. Campos L., Rouault J. P., Sabido O., Oriol P., Roubi N., Vasselon C., Archimbaud E., Magaud J. P., Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993 Jun 1;81(11):3091–3096. [PubMed] [Google Scholar]
  9. Clark J. W. Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. Semin Oncol. 1997 Oct;24(5 Suppl 18):S18–19-S18-24. [PubMed] [Google Scholar]
  10. Costa A., Doci R., Mochen C., Bignami P., Faranda A., Gennari L., Silvestrini R. Cell proliferation-related markers in colorectal liver metastases: correlation with patient prognosis. J Clin Oncol. 1997 May;15(5):2008–2014. doi: 10.1200/JCO.1997.15.5.2008. [DOI] [PubMed] [Google Scholar]
  11. Costa A., Licitra L., Veneroni S., Daidone M. G., Grandi C., Cavina R., Molinari R., Silvestrini R. Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. Int J Cancer. 1998 Dec 18;79(6):619–623. doi: 10.1002/(sici)1097-0215(19981218)79:6<619::aid-ijc11>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  12. Costa A., Marasca R., Valentinis B., Savarino M., Faranda A., Silvestrini R., Torelli G. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol. 1995 May;176(1):45–53. doi: 10.1002/path.1711760108. [DOI] [PubMed] [Google Scholar]
  13. Daidone M. G., Veneroni S., Benini E., Tomasic G., Coradini D., Mastore M., Brambilla C., Ferrari L., Silvestrini R. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int J Cancer. 1999 Dec 22;84(6):580–586. doi: 10.1002/(sici)1097-0215(19991222)84:6<580::aid-ijc7>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  14. De Angelis P. M., Stokke T., Thorstensen L., Lothe R. A., Clausen O. P. Apoptosis and expression of Bax, Bcl-x, and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas, and association with p53 genotype/phenotype. Mol Pathol. 1998 Oct;51(5):254–261. doi: 10.1136/mp.51.5.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Dive C., Hickman J. A. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer. 1991 Jul;64(1):192–196. doi: 10.1038/bjc.1991.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells. 1990 Aug-Sep;2(8-9):275–280. [PubMed] [Google Scholar]
  17. Farczádi E., Szántó J., Kaszás I., Benyó I., Bodnár Z., Szlobodnyik J., Szende B. Changes in apoptotic and mitotic activity in rectal carcinoma after short-term cytostatic therapy as possible predictive factors. Neoplasma. 1999;46(4):219–223. [PubMed] [Google Scholar]
  18. Forster S., Sattler H. P., Hack M., Romanakis K., Rohde V., Seitz G., Wullich B. Microsatellite instability in sporadic carcinomas of the proximal colon: association with diploid DNA content, negative protein expression of p53, and distinct histomorphologic features. Surgery. 1998 Jan;123(1):13–18. [PubMed] [Google Scholar]
  19. Fracchiolla N. S., Capaccio P., Carboni N., Pagliari A. V., Neri A., Ronchett D., Pruner G., Silvotti M. G., Pignataro L., Buffa R. Immunohistochemical and molecular analysis of bax, bcl-2 and p53 genes in laryngeal squamous cell carcinomas. Anticancer Res. 1999 Mar-Apr;19(2A):1043–1051. [PubMed] [Google Scholar]
  20. Gasparini G., Bevilacqua P., Bonoldi E., Testolin A., Galassi A., Verderio P., Boracchi P., Guglielmi R. B., Pezzella F. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res. 1995 Nov;1(11):1375–1383. [PubMed] [Google Scholar]
  21. Gavrieli Y., Sherman Y., Ben-Sasson S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992 Nov;119(3):493–501. doi: 10.1083/jcb.119.3.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hall P. A. Assessing apoptosis: a critical survey. Endocr Relat Cancer. 1999 Mar;6(1):3–8. doi: 10.1677/erc.0.0060003. [DOI] [PubMed] [Google Scholar]
  23. Homma A., Furuta Y., Oridate N., Nakano Y., Kohashi G., Yagi K., Nagahashi T., Yagi K., Nagahashi T., Fukuda S. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res. 1999 Apr;5(4):801–806. [PubMed] [Google Scholar]
  24. Johnston P. G., Liang C. M., Henry S., Chabner B. A., Allegra C. J. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res. 1991 Dec 15;51(24):6668–6676. [PubMed] [Google Scholar]
  25. Kawasaki H., Altieri D. C., Lu C. D., Toyoda M., Tenjo T., Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998 Nov 15;58(22):5071–5074. [PubMed] [Google Scholar]
  26. Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V. M., Niskanen E., Nordling S., Reed J. C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 1995 Oct 1;55(19):4471–4478. [PubMed] [Google Scholar]
  27. Langlois N. E., Lamb J., Eremin O., Heys S. D. Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: relationship to prognosis, mitosis, and immunohistochemical demonstration of p53, c-myc and bcl-2 protein products. J Pathol. 1997 Aug;182(4):392–397. doi: 10.1002/(SICI)1096-9896(199708)182:4<392::AID-PATH874>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  28. Liang J. T., Chang K. J., Chen J. C., Lee C. C., Cheng Y. M., Hsu H. C., Chien C. T., Wang S. M. Clinicopathologic and carcinogenetic appraisal of DNA replication error in sporadic T3N0M0 stage colorectal cancer after curative resection. Hepatogastroenterology. 1999 Mar-Apr;46(26):883–890. [PubMed] [Google Scholar]
  29. Lukish J. R., Muro K., DeNobile J., Katz R., Williams J., Cruess D. F., Drucker W., Kirsch I., Hamilton S. R. Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg. 1998 Jan;227(1):51–56. doi: 10.1097/00000658-199801000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Machiavelli M., Leone B. A., Romero A., Rabinovich M. G., Vallejo C. T., Bianco A., Pérez J. E., Rodríguez R., Cuevas M. A., Alvarez L. A. Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone. Am J Clin Oncol. 1991 Jun;14(3):211–217. [PubMed] [Google Scholar]
  31. Matsuura T., Fukuda Y., Fujitaka T., Nishisaka T., Sakatani T., Ito H. Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma. Cancer. 2000 Mar 1;88(5):1007–1015. doi: 10.1002/(sici)1097-0142(20000301)88:5<1007::aid-cncr9>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  32. McDonnell T. J., Troncoso P., Brisbay S. M., Logothetis C., Chung L. W., Hsieh J. T., Tu S. M., Campbell M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992 Dec 15;52(24):6940–6944. [PubMed] [Google Scholar]
  33. Nelson N. J. Quest for new and better colon cancer treatments picks up steam. J Natl Cancer Inst. 1998 Dec 16;90(24):1858–1859. doi: 10.1093/jnci/90.24.1858. [DOI] [PubMed] [Google Scholar]
  34. Newland R. C., Dent O. F., Lyttle M. N., Chapuis P. H., Bokey E. L. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer. 1994 Apr 15;73(8):2076–2082. doi: 10.1002/1097-0142(19940415)73:8<2076::aid-cncr2820730811>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  35. Ofner D., Riehemann K., Maier H., Riedmann B., Nehoda H., Tötsch M., Böcker W., Jasani B., Schmid K. W. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer. 1995 Oct;72(4):981–985. doi: 10.1038/bjc.1995.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Ogura E., Senzaki H., Yamamoto D., Yoshida R., Takada H., Hioki K., Tsubura A. Prognostic significance of Bcl-2, Bcl-xL/S, Bax and Bak expressions in colorectal carcinomas. Oncol Rep. 1999 Mar-Apr;6(2):365–369. doi: 10.3892/or.6.2.365. [DOI] [PubMed] [Google Scholar]
  37. Orlandi L., Bearzatto A., Abolafio G., De Marco C., Daidone M. G., Zaffaroni N. Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex. Br J Cancer. 1999 Sep;81(2):252–260. doi: 10.1038/sj.bjc.6690685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Paradiso A., Rabinovich M., Vallejo C., Machiavelli M., Romero A., Perez J., Lacava J., Cuevas M. A., Rodriquez R., Leone B. p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer. 1996 Dec 20;69(6):437–441. doi: 10.1002/(SICI)1097-0215(19961220)69:6<437::AID-IJC2>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  39. Paradiso A., Simone G., Petroni S., Leone B., Vallejo C., Lacava J., Romero A., Machiavelli M., De Lena M., Allegra C. J. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer. 2000 Feb;82(3):560–567. doi: 10.1054/bjoc.1999.0964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Petrelli N. J. It is time to stratify with prognostic factors for hepatic metastases. J Clin Oncol. 1995 Sep;13(9):2471–2472. doi: 10.1200/JCO.1995.13.9.2471. [DOI] [PubMed] [Google Scholar]
  41. Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J. C., Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997 Feb 14;275(5302):967–969. doi: 10.1126/science.275.5302.967. [DOI] [PubMed] [Google Scholar]
  42. Silvestrini R., Daidone M. G., Veneroni S., Benini E., Scarfone G., Zanaboni F., Villa A., Presti M., Danese S., Bolis G. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer. 1998 Jan 1;82(1):159–167. [PubMed] [Google Scholar]
  43. Silvestrini R., Veneroni S., Daidone M. G., Benini E., Boracchi P., Mezzetti M., Di Fronzo G., Rilke F., Veronesi U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994 Apr 6;86(7):499–504. doi: 10.1093/jnci/86.7.499. [DOI] [PubMed] [Google Scholar]
  44. Sionov R. V., Haupt Y. The cellular response to p53: the decision between life and death. Oncogene. 1999 Nov 1;18(45):6145–6157. doi: 10.1038/sj.onc.1203130. [DOI] [PubMed] [Google Scholar]
  45. Sturm I., Köhne C. H., Wolff G., Petrowsky H., Hillebrand T., Hauptmann S., Lorenz M., Dörken B., Daniel P. T. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol. 1999 May;17(5):1364–1374. doi: 10.1200/JCO.1999.17.5.1364. [DOI] [PubMed] [Google Scholar]
  46. Sugamura K., Makino M., Kaibara N. Apoptosis as a prognostic factor in colorectal carcinoma. Surg Today. 1998;28(2):145–150. doi: 10.1007/s005950050096. [DOI] [PubMed] [Google Scholar]
  47. Sugamura K., Makino M., Shirai H., Kimura O., Maeta M., Itoh H., Kaibara N. Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5-fluorouracil. Cancer. 1997 Jan 1;79(1):12–17. [PubMed] [Google Scholar]
  48. Tai Y. T., Lee S., Niloff E., Weisman C., Strobel T., Cannistra S. A. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol. 1998 Aug;16(8):2583–2590. doi: 10.1200/JCO.1998.16.8.2583. [DOI] [PubMed] [Google Scholar]
  49. Takano Y., Saegusa M., Ikenaga M., Mitomi H., Okayasu I. Apoptosis of colon cancer: comparison with Ki-67 proliferative activity and expression of p53. J Cancer Res Clin Oncol. 1996;122(3):166–170. doi: 10.1007/BF01366957. [DOI] [PubMed] [Google Scholar]
  50. Tang R., Wang J. Y., Chen J. S., Chang-Chien C. R., Tang S., Lin S. E., You Y. T., Hsu K. C., Ho Y. S., Fan H. A. Survival impact of lymph node metastasis in TNM stage III carcinoma of the colon and rectum. J Am Coll Surg. 1995 Jun;180(6):705–712. [PubMed] [Google Scholar]
  51. Tannapfel A., Nüsslein S., Fietkau R., Katalinic A., Köckerling F., Wittekind C. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):585–591. doi: 10.1016/s0360-3016(98)00076-5. [DOI] [PubMed] [Google Scholar]
  52. Teixeira C., Reed J. C., Pratt M. A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 1995 Sep 1;55(17):3902–3907. [PubMed] [Google Scholar]
  53. Tenjo T., Toyoda M., Okuda J., Watanabe I., Yamamoto T., Tanaka K., Ohtani M., Nohara T., Kawasaki H., Tanigawa N. Prognostic significance of p27(kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology. 2000;58(1):45–51. doi: 10.1159/000012078. [DOI] [PubMed] [Google Scholar]
  54. Yamane N., Makino M., Kaibara N. S-phase accumulation precedes apoptosis induced by preoperative treatment with 5-fluorouracil in human colorectal carcinoma cells. Cancer. 1999 Jan 15;85(2):309–317. doi: 10.1002/(sici)1097-0142(19990115)85:2<309::aid-cncr7>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  55. Yunis J. J., Mayer M. G., Arnesen M. A., Aeppli D. P., Oken M. M., Frizzera G. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med. 1989 Apr 20;320(16):1047–1054. doi: 10.1056/NEJM198904203201605. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES